Skip to content

Author

I. G. Fernandez

We have 4 of 17 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy

The observed association between elevated Lp(a) levels and statin use is primarily driven by confounding by indication, reflecting the patients' higher baseline risk profile rather than a direct biological effect of the medication.

A. M. Hernandez, F. Santiago, J. M. Andreu Cayuelas et al. · 0 citations
Open access Oct 2026

Benefit of upfront combination lipid-lowering therapy in statin-naïve acute coronary syndrome patients with intermediate admission LDL-C and Lp(a)-driven predicted monotherapy failure

The proportion of LLT-naïve ACS patients eligible for upfront combination therapy due to Lp(a)-driven predicted monotherapy failure (Lp(a)-PMF) is identified, and the real-world benefit of this strategy in achieving the absolute therapeutic target (LDL-C <55 mg/dL) is evaluated.

F. B. Santiago, J. M. Andreu Cayuelas, A. M. Hernandez et al. · 0 citations
Open access Oct 2026

Association of apolipoprotein B and lipoprotein(a) with severe atherosclerotic cardiovascular disease in patients with acute coronary syndrome: the modifying effect of prior lipid-lowering therapy.

In ACS patients, the predictive value of lipid biomarkers for disease severity is fundamentally modified by prior LLT, and in patients on prior LLT, Lp(a) emerged as a strong independent predictor of severe ASCVD, whereas lower apoB levels were paradoxically associated with higher disease burden, likely reflecting more...

A. M. Hernandez, F. Santiago, J. M. Andreu Cayuelas et al. · 0 citations
Open access Oct 2026

Upfront combination lipid-lowering therapy in statin-naive acute coronary syndrome patients with high admission LDL-C: real-world support for the 2025 ESC dyslipidaemias guidelines

The findings strongly support the 2025 ESC/EAS Guidelines update: in patients with LDL-PMF, adding ezetimibe to high-intensity statins at discharge significantly increases the likelihood of achieving the <55 mg/dL target compared to monotherapy.

A. M. Hernandez, J. M. Andreu Cayuelas, F. B. Santiago et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.